Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

Roberto M. Lang, Michelle Bierig, Richard B. Devereux et al. · Journal of the American Society of Echocardiography · 2005 · 11.3K citations

Medicine, Cardiology, Clinical Cardiology +14

Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults

Barry J. Maron, Julius M. Gardin, John M. Flack et al. · Circulation · 1995 · 2.3K citations · Full text

Medicine, Cardiology, Internal Medicine +7

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

Bernard J. Gersh, Barry J. Maron, Robert O. Bonow et al. · Circulation · 2011 · 2.1K citations · Full text

Medicine, Cardiology, Internal Medicine +9

A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)

Constantinos O’Mahony, Fatima Jichi, Menelaos Pavlou et al. · European Heart Journal · 2013 · 1.2K citations · Full text

Business, Biostatistics, Cardiology +17

Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy

Paolo Spirito, Pietro Bellone, Kevin M. Harris et al. · New England Journal of Medicine · 2000 · 1.1K citations · Full text

Medicine, Cardiology, Internal Medicine +14